Stoke Therapeutics (NASDAQ:STOK) Insider Barry Ticho Sells 7,176 Shares of Stock

Stoke Therapeutics, Inc. (NASDAQ:STOK) insider Barry Ticho sold 7,176 shares of the stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $29.04, for a total value of $208,391.04. Following the completion of the sale, the insider owned 20,422 shares in the company, valued at $593,054.88. This trade represents a 26.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Barry Ticho also recently made the following trade(s):

• On Monday, June 1st, Barry Ticho sold 1,795 shares of Stoke Therapeutics stock. The stock was sold at an average price of $30.58, for a total value of $54,891.10.

Stoke Therapeutics Stock Up 0.8%

Shares of NASDAQ STOK opened at $31.93 on Thursday. The stock’s 50-day simple moving average is $30.41 and its two-hundred day simple moving average is $32.03. Stoke Therapeutics, Inc. has a twelve month low of $12.75 and a twelve month high of $40.22. The firm has a market capitalization of $1.99 billion, a P/E ratio of -9.56 and a beta of 1.20.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings results on Monday, August 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.80) by ($0.13). Stoke Therapeutics had a negative net margin of 753.60% and a negative return on equity of 59.36%. The business had revenue of $9.32 million for the quarter, compared to the consensus estimate of $4.89 million. As a group, research analysts anticipate that Stoke Therapeutics, Inc. will post -3.22 EPS for the current fiscal year.

Institutional Trading of Stoke Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Kestra Advisory Services LLC purchased a new stake in Stoke Therapeutics during the fourth quarter valued at about $26,000. KBC Group NV purchased a new position in shares of Stoke Therapeutics in the first quarter worth about $36,000. Harbour Investments Inc. increased its holdings in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock worth $38,000 after buying an additional 898 shares during the period. BNP Paribas Financial Markets lifted its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock valued at $48,000 after acquiring an additional 1,668 shares during the last quarter. Finally, Tower Research Capital LLC TRC lifted its stake in shares of Stoke Therapeutics by 461.0% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company’s stock valued at $50,000 after acquiring an additional 3,591 shares during the last quarter.

Stoke Therapeutics News Roundup

Here are the key news stories impacting Stoke Therapeutics this week:

• Positive Sentiment: Guggenheim reaffirmed its “buy” rating and set a $60 price target, while Wedbush raised its target to $40 and maintained an “outperform” rating. Chardan also reiterated “buy,” and Canaccord maintained “buy” despite trimming its target to $58. The targets imply substantial upside from recent trading levels. Analyst rating and price-target updates
• Positive Sentiment: Management’s second-quarter update highlighted plans to submit a rolling NDA for zorevunersen in the first quarter of 2027, supporting a potential U.S. launch by early 2028. The company also reported approximately $420 million in cash, which could fund development and launch preparation. Stoke outlines rolling NDA and cash position
• Positive Sentiment: A bullish research commentary cited the potential for the zorevunersen NDA in SCN1A-related Dravet syndrome and continued advancement of STK-002, reinforcing the company’s pipeline-driven investment case. Stoke buy thesis on zorevunersen and STK-002
• Neutral Sentiment: Stoke is scheduled to present at the Canaccord Genuity 46th Annual Growth Conference, providing an opportunity for management to discuss its clinical and regulatory plans with investors. Stoke Therapeutics conference presentation
• Negative Sentiment: Stoke reported a second-quarter loss of $0.93 per share versus the $0.80 consensus estimate, although revenue of $9.33 million exceeded expectations. HC Wainwright subsequently reduced its FY2029 EPS estimate to $1.55 from $1.63 and its FY2030 estimate to $3.56 from $3.74. Stoke Therapeutics Q2 2026 earnings call summary
• Negative Sentiment: Director Barry Ticho sold 7,176 shares worth approximately $208,000, reducing his direct stake by 26%. The transaction was made under a pre-arranged Rule 10b5-1 plan, which lessens its negative significance but may still weigh modestly on sentiment. SEC insider sale filing

Analyst Ratings Changes

Several analysts have recently weighed in on STOK shares. Chardan Capital restated a “buy” rating and set a $35.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday. Guggenheim reissued a “buy” rating and issued a $60.00 target price on shares of Stoke Therapeutics in a research note on Tuesday. Wedbush lifted their price target on Stoke Therapeutics from $38.00 to $40.00 and gave the stock an “outperform” rating in a research note on Tuesday. Canaccord Genuity Group cut their price objective on Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a report on Tuesday. Finally, The Goldman Sachs Group assumed coverage on Stoke Therapeutics in a report on Monday, July 13th. They set a “buy” rating and a $44.00 price objective on the stock. Nine analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $43.00.

About Stoke Therapeutics

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.